Bug ETF holdings refer to the specific stocks and their weightings within the ARK Genomic Revolution ETF (ticker: BUG), a U.S.-listed exchange-traded fund focused on biotechnology, genomics, and related innovation sectors. The fund holds 68 individual securities, with top positions in companies like CRISPR Therapeutics, Editas Medicine, and Alnylam Pharmaceuticals.
Bug ETF holdings are actively managed, meaning the portfolio is adjusted regularly based on research-driven decisions rather than tracking a static index. The fund's mandate centers on long-term growth in genetic medicine, gene editing, and precision therapies. As of Q1 2024, the top five holdings accounted for 42% of total assets, with CRISPR Therapeutics making up 14.7% of the portfolio.
Unlike passive funds such as the S&P 500 ETF (SPY), which mirror a broad market index, Bug ETF holdings reflect a concentrated bet on emerging science and high-risk, high-reward biotech firms. This focus results in higher volatility compared to diversified equity ETFs. For example, during the 2022 market downturn, BUG declined 58% year-over-year, while SPY dropped 19%.
The ARK Investment Management team selects Bug ETF holdings based on proprietary research into breakthrough technologies. They assess each company's pipeline, regulatory pathway, and potential market size. Holdings are rebalanced quarterly, with new additions and exits driven by clinical trial results, FDA approvals, and competitive positioning.
For instance, in March 2023, ARK added shares of Beam Therapeutics, a gene-editing firm using base editing technology, after positive Phase 1 data for a rare disease treatment. Conversely, they exited positions in companies like Bluebird Bio following delayed approval timelines for their gene therapy products.
Portfolio turnover is high-averaging 120% annually-indicating frequent trading activity. This contrasts sharply with low-turnover passive ETFs, which may hold the same stocks for years. High turnover increases transaction costs and tax implications for investors, though ARK argues it enables faster adaptation to scientific progress.
Bug ETF holdings fall into four primary categories based on therapeutic approach and stage of development:
| Type | Examples | Weight (Q1 2024) | Key Risk |
|---|---|---|---|
| Gene Editing (CRISPR-based) | CRISPR Therapeutics, Editas Medicine | 21% | Off-target effects in trials |
| RNA Interference (RNAi) | Alnylam Pharmaceuticals, Arrowhead Research | 18% | Delivery challenges to tissues |
| Gene Therapy (AAV vectors) | Spark Therapeutics, Bluebird Bio | 15% | Immune response risks |
| Next-Gen Diagnostics | Grail (Illumina subsidiary), Guardant Health | 12% | Regulatory hurdles for early detection |
These categories reflect ARK's belief that genetic medicine will reshape healthcare in the next decade. The fund avoids pure-play pharmaceuticals and focuses on platforms with scalability, such as CRISPR's ability to treat multiple diseases from a single toolset.
Tracking Bug ETF holdings reveals exposure to major science. For example, in late 2023, the fund increased its stake in CRISPR Therapeutics after the company reported successful Phase 2 results for treating sickle cell disease. The stock rose 40% in three weeks, contributing to BUG's 15% monthly gain that month.
Investors use holdings data to gauge risk concentration. A single failed trial can trigger sharp declines-such as when Alnylam's drug for hereditary transthyretin amyloidosis (hATTR) faced safety concerns in 2021, causing a 30% drop in the stock and dragging down the ETF.
A common misconception is that Bug ETF holdings are synonymous with ARK's other funds. While BUG focuses on genomic medicine, ARK's flagship ETF (ARKK) holds 100+ stocks across robotics, AI, and fintech. For example, Tesla appears in ARKK but not in BUG. Confusing the two leads to misaligned expectations about risk and growth drivers.
Many assume Bug ETF holdings are dominated by large-cap biopharma giants like Johnson & Johnson or Pfizer. In reality, the top 10 holdings include only two companies with market caps above $10 billion. The majority are small- to mid-cap firms with limited revenue, relying heavily on venture funding and partnerships.
Another error is equating holding percentage with investment size. For example, CRISPR Therapeutics makes up 14.7% of BUG's assets, but the actual dollar value of that position was $187 million as of March 31, 2024. That's less than 1% of the entire ARK family's $20 billion in assets under management.
I've monitored Bug ETF holdings since 2020. In 2021, the fund added shares of Intellia Therapeutics after a landmark CRISPR trial showed sustained reduction in transthyretin protein levels. The stock nearly doubled over six months, validating ARK's forward-looking strategy. But I also saw the downside-when a similar trial failed in 2022, the loss was immediate and painful.
Bug ETF holdings differ from those in the iShares Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI). While all three focus on biotech, their approaches diverge:
| Fund | Focus | Top Holding (Q1 2024) | Holdings Type |
|---|---|---|---|
| Bug (BUG) | Genomics, gene editing, RNAi | CRISPR Therapeutics (14.7%) | High-growth, early-stage |
| IBB | Broad biotech, including pharma | Amgen (3.4%) | Diversified, large-cap |
| XBI | Biotech innovation, mid-cap focus | Vertex Pharmaceuticals (2.9%) | Mixed, moderate risk |
IBB and XBI are passively managed, tracking indices that include both mature drug developers and startups. Bug ETF holdings are actively selected, favoring companies with platform technologies over single-product firms. This difference explains why BUG has outperformed IBB by 4.2% annually over the past five years, despite higher volatility.
Bug ETF holdings represent a concentrated, forward-looking view of genetic medicine's potential. They are not a substitute for diversified portfolios but serve as a vehicle for investors seeking exposure to science-driven innovation. Understanding these holdings requires attention to clinical milestones, regulatory timelines, and management decisions-not just price movements.